Search Result

Isoforms Recommended:	CDK6

Results for "

CDK6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (2) AMPK (1) Apoptosis (9) Aurora Kinase (1) CaMK (1) Casein Kinase (1) CDK (59) Cyclin G-associated Kinase (GAK) (1) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (1) Epigenetic Reader Domain (2) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (1) FLT3 (1) Glutathione Peroxidase (1) GSK-3 (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (2) NF-κB (1) PDGFR (1) PI3K (1) Pim (1) PROTACs (11) Salt-inducible Kinase (SIK) (2) Small Interfering RNA (siRNA) (3) ULK (1) Wee1 (2)
By Research Areas:	Cancer (63) Metabolic Disease (1)
Click Chemistry:	Azide (1) Alkynes (2)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS02392

CDK6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK6 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK6 Human Pre-designed siRNA Set A CDK6 Human Pre-designed siRNA Set A

HY-RS02393

Cdk6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk6 Mouse Pre-designed siRNA Set A Cdk6 Mouse Pre-designed siRNA Set A

HY-RS02394

Cdk6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk6 Rat Pre-designed siRNA Set A Cdk6 Rat Pre-designed siRNA Set A

HY-142696

CDK6/PIM1-IN-1	CDK Pim Apoptosis	Cancer
CDK6/PIM1-IN-1 is a potent and balanced dual *CDK6/PIM1* inhibitor with IC₅₀ values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC₅₀=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .

HY-131063

CDK6/9-IN-1	CDK	Cancer
CDK6/9-IN-1 (compound 66) is an orally active active and dual *CDK 6* and CDK 9 inhibitor, with IC₅₀ values of 40.5 nM and 39.5 nM for CDK6 anmd CDK9, respectively .

HY-130296

Palbociclib-propargyl PROTAC CDK6 ligand 1	Ligands for Target Protein for PROTAC	Cancer
Palbociclib-propargyl is a ligand for target protein *CDK6* for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC₅₀ of 2.1 nM for CDK6 . Palbociclib-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-112272A

Lerociclib dihydrochloride 1 Publications Verification G1T38 dihydrochloride	CDK	Cancer
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of *CDK4/CDK6*, with IC₅₀s of 1 nM and 2 nM for *CDK4/CyclinD1* and *CDK6/CyclinD3*, respectively.

HY-139450

PF-07220060 CDK4/6-IN-6	CDK	Cancer
PF-07220060 (CDK4/6-IN-6; example A94) is a potent *CDK4/CDK6* inhibitor with a K_i of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively .

HY-50767S

Palbociclib-d8 PD 0332991-d₈	CDK	Cancer
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-139449

CDK4/6-IN-5	CDK	Cancer
CDK4/6-IN-5 is a potent *CDK4* and *CDK6* inhibitor with K_is of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively . (from patent WO2019207463A1 example A93).

HY-114339

CDK4/6-IN-2	CDK	Cancer
CDK4/6-IN-2 is a potent *CDK4* and *CDK6* inhibitor extracted from patent US20180000819A1, Compound 1, has IC₅₀s of 2.7 and 16 nM for CDK4 and CDK6, respectively .

HY-163272

*GPX4/CDK-IN-1*	Glutathione Peroxidase CDK	Cancer
GPX4/CDK-IN-1 (Compound B9) is a dual inhibitor of GPX4 and *CDK, with IC₅₀* values of 542.5 nM, 191.2 nM and 68.1 nM for GPX4, CDK4 and CDK6, reapectively. GPX4/CDK-IN-1 shows strong cancer cell growth inhibition in vivo .

HY-111556

BSJ-03-123 2 Publications Verification	PROTACs CDK	Cancer
BSJ-03-123 is a PROTAC connected by ligands for Cereblon and *CDK* as a potent and novel *CDK6*-selective small-molecule degrader.

HY-125835

CP-10 1 Publications Verification	PROTACs CDK	Cancer
CP-10 is a PROTAC connected by ligands for Cereblon and *CDK, with highly selective, specific, and remarkable CDK6* degradation (DC₅₀=2.1 nM). It inhibits proliferation of several haematopoietic cancer cells with impressive potency including multiple myeloma, and can still degrades mutated and overexpressed CDK6 .

HY-16297A

Abemaciclib

70+ Cited Publications

LY2835219
CDK Cancer

Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

Abemaciclib 70+ Cited Publications LY2835219	CDK	Cancer
Abemaciclib (LY2835219) is a selective *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective *CDK4* and *CDK6* (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-136252

BSJ-04-132	PROTACs CDK	Cancer
BSJ-04-132 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4* degrader (PROTAC), with IC₅₀s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity .

HY-108907

SR-1277	Casein Kinase	Cancer
SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC₅₀s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC₅₀s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .

HY-112272

Lerociclib

G1T38
CDK Cancer

Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC₅₀s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

Lerociclib G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of *CDK4/6, with IC₅₀s* of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

HY-148213

CDK2/4/6-IN-1	CDK	Cancer
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-143258

CDK4/6-IN-8

CDK Cancer

CDK4/6-IN-8 (Compound 7p) is a selective CDK4 and CDK6 inhibitor with IC₅₀ values of 5.01 nM and 3.97 nM, respectively .

CDK4/6-IN-8	CDK	Cancer
CDK4/6-IN-8 (Compound 7p) is a selective *CDK4* and *CDK6* inhibitor with IC₅₀ values of 5.01 nM and 3.97 nM, respectively .

HY-131466

N-Methyl Palbociclib	Drug Metabolite	Others
N-Methyl Palbociclib is an impurity of Palbociclib (HY-50767). Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor.

HY-16297

Abemaciclib methanesulfonate 70+ Cited Publications LY2835219 methanesulfonate	CDK	Cancer
Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective *CDK4/6* inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-50943

AT7519 Hydrochloride 5+ Cited Publications	CDK Apoptosis	Cancer
AT7519 Hydrochloride is a potent inhibitor of *CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK*9, respectively.

HY-16297AS

Abemaciclib-d8 LY2835219-d₈	CDK	Cancer
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-50940

AT7519 5+ Cited Publications AT7519M	CDK Apoptosis	Cancer
AT7519 (AT7519M) as a potent inhibitor of *CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK*9, respectively.

HY-128669

Abemaciclib metabolite M2 1 Publications Verification LSN2839567	CDK Drug Metabolite	Cancer
Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent *CDK4* and *CDK6* inhibitor, with IC₅₀s of 1.2 and 1.3 nM, respectively. Anti-cancer activity .

HY-50940A

AT7519 TFA 5+ Cited Publications AT7519M TFA	CDK	Cancer
AT7519 (AT7519M) TFA as a potent inhibitor of *CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK*9, respectively.

HY-126244

CDK4/6-IN-3	CDK	Cancer
CDK4/6-IN-3 is a brain-penetrant *CDK4/CDK6* inhibitor with K_is of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a K_i of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma .

HY-111361

FN-1501 1 Publications Verification	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and *CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6*/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

HY-116035

Nimbolide 1 Publications Verification	NF-κB CDK Apoptosis	Cancer
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-114177

Ebvaciclib 2 Publications Verification PF-06873600	CDK	Cancer
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase *(CDK), with K_i* values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .

HY-115942

Anticancer agent 29	CDK	Cancer
Anticancer agent 29 (Compd E/Z-6f) is an anticancer agent, with IC₅₀ values of 0.054 μM, 0.127 μM, 0.129 μM, 0.396 μM for CDK2, CDK1, CDK4 and CDK6, respectively .

HY-10012

AZD-5438 5+ Cited Publications	CDK	Cancer
AZD-5438 is a potent *CDK1, CDK2, and CDK9* inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-50767S1

Palbociclib-d4 hydrochloride PD 0332991-d₄ hydrochloride	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent *CDK4* and *CDK6* inhibitor, with an IC₅₀ of 0.013 μM for *CDK4. CDK4/6-IN-16 can be used for the research of CDK*4-mediated disorders, such as cancer .

HY-N0636

Eriocitrin 1 Publications Verification	Apoptosis	Cancer
Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .

HY-N1986

Cucurbitacin D
Cucurbitacin D is an active component in Trichosanthes kirilowii, disrupts interactions between Hsp90 and two co-chaperones, Cdc37 and p23. Cucurbitacin D prevents Hsp90 client (Her2, Raf, Cdk6, pAkt) maturation without induction of the heat shock response. Anti-cancer activity .

HY-12624

Narazaciclib 2 Publications Verification ON123300	CDK AMPK PDGFR	Cancer
Narazaciclib (ON123300), a strong and brain-penetrant multi-kinase inhibitor, inhibits *CDK4* (IC₅₀=3.9 nM), Ark5 (IC₅₀=5 nM), PDGFRβ (IC₅₀=26 nM), FGFR1 (IC₅₀=26 nM), RET (IC₅₀=9.2 nM), and FYN (IC₅₀=11 nM). Single agent Narazaciclib causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors . Narazaciclib inhibits *CDK6* with an IC₅₀ of 9.82 nM .

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .

HY-128669S

Abemaciclib metabolite M2-d6 LSN2839567-d₆	CDK	Cancer
Abemaciclib metabolite M2-d₆ is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity[1][2].

HY-115993

CDK4/6-IN-10	CDK Apoptosis	Cancer
CDK4/6-IN-10 is a potent, selective and orally active *CDK4* and *CDK6* inhibitor with IC₅₀s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM) .

HY-101467A

Trilaciclib hydrochloride 1 Publications Verification G1T28 hydrochloride	CDK	Cancer
Trilaciclib (G1T28) hydrochloride is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-101467

Trilaciclib 1 Publications Verification G1T28	CDK	Cancer
Trilaciclib (G1T28) is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-148530

YX-2-107	PROTACs CDK	Cancer
YX-2-107 is a PROTAC (IC₅₀= 4.4 nM) that selectively degrades *CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1* expression in vitro and inhibits the development of Ph ⁺ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph ⁺) acute lymphoblastic leukemia (ALL) .

HY-136250

BSJ-03-204	PROTACs CDK	Cancer
BSJ-03-204 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6* dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity .

HY-50767

Palbociclib Maximum Cited Publications 134 Publications Verification PD 0332991	CDK	Cancer
Palbociclib (PD 0332991) is an orally active selective *CDK4* and *CDK6* inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767B

Palbociclib dihydrochloride PD-0332991 dihydrochloride	CDK	Cancer
Palbociclib (PD 0332991) dihydrochloride is an orally active selective *CDK4* and *CDK6* inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-116035

Nimbolide 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Azadirachta indica A. Juss. Disease Research Fields Meliaceae Cancer	NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N0636

Eriocitrin 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Citrus limon (L.) Burm. F. Flavonones Source classification Rutaceae Phenols Polyphenols Plants Disease Research Fields Cancer	Apoptosis
Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 6 (CDK6)

Species:	Human (7)
Tag:	His (4) Tag Free (3) Avi (1) GST (3) Flag (2)
Source:	Sf9 insect cells (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P702601

CDK6 Protein, Human (Sf9, His-Avi)

Cyclin-dependent kinase 6; Cell division protein kinase 6; CDKN6; EC:2.7.11.22
Human Sf9 insect cells

HY-P701367

	CDK6-CCND2 Heterodimer Protein, Human (Sf9) CDK6; CCND2; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D2	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND2 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND2 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P701369

	CDK6-CCND3 Heterodimer Protein, Human (Sf9) CDK6; CCND3; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D3	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND3 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND3 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P701368

	CDK6-CCND2 Heterodimer Protein, Human (Sf9, GST, FLAG, His) CDK6; CCND2; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D2	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND2 Heterodimer Protein, Human (Sf9, GST, FLAG, His) is a recombinant protein dimer complex containing human-derived CDK6-CCND2 Heterodimer protein, expressed by Sf9 insect cells , with N-Flag, N-8*His, N-GST labeled tag.

HY-P701370

	CDK6-CCND3 Heterodimer Protein, Human (Sf9, GST, His) CDK6; CCND3; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D3	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND3 Heterodimer Protein, Human (Sf9, GST, His) is a recombinant protein dimer complex containing human-derived CDK6-CCND3 Heterodimer protein, expressed by Sf9 insect cells , with N-10*His, N-GST labeled tag.

HY-P702687

	CDK6-CCND1 Protein, Human (sf9, GST, Flag, His) CDK6; CCND2; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D2	Human	Sf9 insect cells

HY-P701366

	CDK6-CCND1 Heterodimer Protein, Human (Sf9) CDK6; CCND1; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

Cat. No.	Product Name	Chemical Structure